NanoString Technologies, Inc. (NSTG) Stock
NanoString Technologies, Inc. is a global innovator in scientific instrumentation, designing and producing advanced research tools for genomics and proteomics across the Americas, Europe, the Middle East, and Asia Pacific.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About NanoString Technologies, Inc.
NanoString Technologies, Inc. is a global innovator in scientific instrumentation, designing and producing advanced research tools for genomics and proteomics across the Americas, Europe, the Middle East, and Asia Pacific. Its flagship offering is the nCounter Analysis System, an automated platform renowned for its versatile digital detection and counting capabilities. This system includes both nCounter MAX and FLEX configurations, which integrate a Prep Station for automated liquid handling and sample preparation, alongside a Digital Analyzer. The Analyzer captures data by imaging fluorescent reporters within sample cartridges, then processes this information into usable output files. The company also offers the nCounter SPRINT Profiler, a compact instrument that streamlines liquid handling and digital analysis using a specialized microfluidic cartridge. Complementing its hardware, NanoString provides nSolver Analysis Software, a powerful program enabling researchers to verify, normalize, and interpret their experimental data. Further extending its product portfolio, NanoString supplies customizable CodeSets and pre-designed panels tailored for applications in oncology, immunology, infectious diseases, and neuroscience. Essential Master Kits, containing reagents and plasticware, are also available to facilitate sample setup and processing within their nCounter Prep Station and Digital Analyzer. Additionally, they market Prosigna molecular diagnostic test kits. Looking ahead, NanoString is actively developing the GeoMx DSP system, poised to advance the field of spatial genomics. The company maintains strategic partnerships, including collaborations with Lam Research Corporation for the research and development of Hyb & Seq technologies, and with Celgene Corporation on LymphMark, an in vitro diagnostic for diffuse large B-cell lymphoma. They also work with the Parker Institute for Cancer Immunotherapy to improve CAR-T regimens and patient outcomes across various cancer types. Established in 2003, NanoString Technologies, Inc. operates from its headquarters in Seattle, Washington.
NanoString Technologies, Inc. is headquartered in US.
NanoString Technologies, Inc. (NSTG) stock trades at $0.11 with a market capitalization of $5.07M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.11, price-to-sales of 0.04. Over the past 52 weeks the stock has ranged between $0.10 and $0.14, and currently trades 21.4% below its 52-week high.
On profitability, NanoString Technologies, Inc. generates a return on equity (ROE) of -143.23%, return on capital employed of -51.67%, an operating margin of -119.58%, a net profit margin of -125.37%.
Official website: www.nanostring.com